Compare TRDA & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | MPAA |
|---|---|---|
| Founded | 2016 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.6M | 253.7M |
| IPO Year | 2021 | 2007 |
| Metric | TRDA | MPAA |
|---|---|---|
| Price | $7.53 | $11.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $21.00 | $17.50 |
| AVG Volume (30 Days) | ★ 382.2K | 107.9K |
| Earning Date | 05-08-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 162.63 |
| EPS | N/A | ★ N/A |
| Revenue | $25,421,000.00 | ★ $789,806,000.00 |
| Revenue This Year | $39.97 | $1.50 |
| Revenue Next Year | $50.80 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.28 |
| 52 Week Low | $5.02 | $9.29 |
| 52 Week High | $16.45 | $18.12 |
| Indicator | TRDA | MPAA |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 30.07 |
| Support Level | $5.71 | $9.91 |
| Resistance Level | $8.04 | $11.99 |
| Average True Range (ATR) | 0.46 | 0.71 |
| MACD | 0.09 | -0.16 |
| Stochastic Oscillator | 70.68 | 39.76 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts, test solutions, and diagnostic equipment. Its replacement parts are mainly sold to automotive retail chain stores, warehouse distributors across North America, and automobile manufacturers for aftermarket and warranty replacement programs. The Company's test solutions and diagnostic equipment serve the automotive component and powertrain testing market. Its product portfolio includes rotating electrical products such as alternators and starters; brake-related products including brake calipers, brake rotors, brake pads, brake master cylinders, and wheel hub assemblies and bearings; and other products. Its segments are Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty.